Iterum Therapeutics plc (ITRMF) EPS (Basic) (2017 - 2025)

Iterum Therapeutics has reported EPS (Basic) for 9 years, with the latest figure at -$0.2 in Q3 2025.

• On a quarterly basis, EPS (Basic) rose 35.52% year-over-year to -$0.2 in Q3 2025; TTM through Sep 2025 was -$0.59, a 61.38% increase from a year earlier, with the FY2024 full-year figure at -$1.26, up 57.52% from the prior year.
• EPS (Basic) was -$0.2 for Q3 2025 at Iterum Therapeutics, down from -$0.16 in the prior quarter.
• The five-year high for EPS (Basic) was $0.31 in Q3 2021, with the low at -$2.38 in Q3 2022.
• Average EPS (Basic) over 5 years is -$0.49, with a median of -$0.33 recorded in 2024.
• The sharpest annual moves came in 2021 and 2022: EPS (Basic) soared 151.33% in 2021, then plunged 1371.87% in 2022.
• Over 5 years, EPS (Basic) stood at -$0.38 in 2021, then fell by 8.33% to -$0.42 in 2022, then slumped by 129.27% to -$0.95 in 2023, then jumped by 64.96% to -$0.33 in 2024, then jumped by 41.33% to -$0.2 in 2025.
• The last three EPS (Basic) figures came in at -$0.2 (Q3 2025), -$0.16 (Q2 2025), and -$0.14 (Q1 2025), per Business Quant data.